Different Clinical Manifestations of Adenoviral Infection Confirmed Using Point-of-Care Testing in a Group of Hospitalized Children
Abstract
:1. Introduction
2. Material and Methods
2.1. Study Design
2.2. Patient Identification and Selection
- Nasopharyngeal swab: Certest Biotec S.L., Spain, Influenza A+ B + RSV + Adeno. (detects serotypes 2, 3, 4, 5, 15, 31, 40, 41). The specimens were collected by trained medical doctors. Results were measured by POC tests.
- Stool: Certest Biotec S.L., Spain, Influenza A+ B + RSV + Adeno. (detects serotypes 2, 5, 15, 31, 40, 41). The test was performed in the microbiology lab of the University Children’s Hospital of Cracow.
2.3. Definitions of the Groups of Patients
2.4. Statistical Methods
3. Results
Laboratory Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lynch, J.P.; Fishbein, M.; Echavarria, M. Adenovirus. Semin. Respir. Crit. Care Med. 2011, 32, 494–511. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.; Xie, Z.; Zhang, T.; Lu, Y.; Fan, H.; Yang, D.; Bénet, T.; Vanhems, P.; Shen, K.; Huang, F.; et al. Comparison of the prevalence of respiratory viruses in patients with acute respiratory infections at different hospital settings in North China, 2012–2015. BMC Infect. Dis. 2018, 18, 72. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rocholl, C.; Gerber, K.; Daly, J.; Pavia, A.T.; Byington, C.L. Adenoviral infections in children: The impact of rapid diagnosis. Pediatrics 2004, 113, e51–e56. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pathogenesis, Epidemiology, and Clinical Manifestations of Adenovirus Infection-UpToDate. Available online: https://www.uptodate.com/contents/pathogenesis-epidemiology-and-clinical-manifestations-of-adenovirus-infection#! (accessed on 17 November 2021).
- Ison, M.G.; Hayden, R.T. Adenovirus. Microbiol. Spectr. 2016, 4, 217–232. [Google Scholar] [CrossRef] [PubMed]
- de Oña, C.G.; Alvarez-Argüelles, M.E.; Rojo-Alba, S.; Casares, H.; Arroyo, M.; Rodríguez, J.; de Oña, M.; Melón, S. Alterations in biochemical markers in adenovirus infection. Transl. Pediatr. 2021, 10, 1248. [Google Scholar] [CrossRef] [PubMed]
- Reischl, A.T.; Schreiner, D.; Poplawska, K.; Kidszun, A.; Zepp, F.; Gröndahl, B.; Gehring, S. The clinical impact of PCR-based point-of-care diagnostic in respiratory tract infections in children. J. Clin. Lab. Anal. 2020, 34, e23203. [Google Scholar] [CrossRef] [Green Version]
- Udeh, B.L.; Schneider, J.E.; Ohsfeldt, R.L. Cost Effectiveness of a Point-of-Care Test for Adenoviral Conjunctivitis. Am. J. Med. Sci. 2008, 336, 254–264. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lion, T. Adenovirus Infections in Immunocompetent and Immunocompromised Patients. Clin. Microbiol. Rev. 2014, 27, 441. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Romero-Gómez, M.P.; López, R.L.; Montes, R.G.; Ruiz, C.O.; Cuesta, S.H.; Crespo, M.A.M.; García, S.G. Immunochromatographic test for detection of adenovirus from respiratory samples: Is it a real solution for pediatric emergency department? J. Virol. Methods 2014, 195, 236. [Google Scholar] [CrossRef] [PubMed]
- Paulini, I.; Siqueira-Silva, J.; Thomaz, L.; Rocha, L.; Harsi, C.; Bellei, N.; Granato, C. Development of a prototype immunochromatographic test for rapid diagnosis of respiratory adenovirus infection. Braz. J. Infect. Dis. 2017, 21, 500–506. [Google Scholar] [CrossRef] [PubMed]
- Adenovirus Respiratory Infection among Immunocompetent Patients in a Pediatric Intensive Care Unit during 10-Year Period: Co-Morbidity Is Common-PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/31542903/ (accessed on 16 November 2021).
- Qiu, F.-Z.; Shen, X.-X.; Li, G.-X.; Zhao, L.; Chen, C.; Duan, S.-X.; Guo, J.-Y.; Zhao, M.-C.; Yan, T.-F.; Qi, J.-J.; et al. Adenovirus associated with acute diarrhea: A case-control study. BMC Infect. Dis. 2018, 18, 450. [Google Scholar] [CrossRef] [PubMed]
- Putto, A.; Meurman, O.; Ruuskanen, O. C-reactive protein in the differentiation of adenoviral, Epstein-Barr viral and streptococcal tonsillitis in children. Eur. J. Pediatr. 1986, 145, 204–206. [Google Scholar] [CrossRef] [PubMed]
- Mistchenko, A.S.; Diez, R.A.; Mariani, A.L.; Robaldo, J.; Maffey, A.F.; Bayley-Bustamante, G.; Grinstein, S. Cytokines in adenoviral disease in children: Association of interleukin-6, interleukin-8, and tumor necrosis factor alpha levels with clinical outcome. J. Pediatr. 1994, 124, 714–720. [Google Scholar] [CrossRef] [PubMed]
- Kawasaki, Y.; Hosoya, M.; Katayose, M.; Suzuki, H. Correlation between serum interleukin 6 and C-reactive protein concentrations in patients with adenoviral respiratory infection. Pediatr. Infect. Dis. J. 2002, 21, 370–374. [Google Scholar] [CrossRef] [PubMed]
- Rajan, A.; Persson, B.D.; Frängsmyr, L.; Olofsson, A.; Sandblad, L.; Heino, J.; Takada, Y.; Mould, A.P.; Schnapp, L.M.; Gall, J.; et al. Enteric Species F Human Adenoviruses use Laminin-Binding Integrins as Co-Receptors for Infection of Ht-29 Cells. Sci. Rep. 2018, 8, 10019. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Watanabe, A.; Carraro, E.; Camargo, C.; Puerari, D.; Guatura, S.; Granato, C.; Bellei, N. Human adenovirus detection among immunocompetent and immunocompromised patients presenting acute respiratory infection. Rev. Soc. Bras. Med. Trop. 2013, 46, 161–165. [Google Scholar] [CrossRef] [PubMed]
Group A (n = 57) | Group B (n = 40) | Group C (n = 38) | p | |
---|---|---|---|---|
Age (months; Median; IQR) | 17 (12–30) | 30 (16–50) | 17 (12–27) | 0.04 * |
Age <12 months 12–24 months >24 months | 15 23 19 | 4 14 22 | 9 19 10 | 0.066 # |
Fever before admission n (%) | 54 (94.7%) | 16 (40%) | 30 (78.9%) | <0.001 # |
Antibiotics before admission n (%) | 24 (42.1%) | 3 (7.5%) | 14 (36.8%) | 0.001 # |
Duration of fever before admission only feverish patients (days; median; IQR) | 3 (1–5) | 1 (1–2) | 3 (1–4) | 0.01 * |
LOS (days), median (IQR) | 4 (3–6) | 3 (3–5) | 4 (3–5) | 0.14 * |
Group A (n = 57) | Group B (n = 40) | Group C (n = 38) | p * | |
---|---|---|---|---|
Positive nasopharyngeal swab for adenovirus antigen | 47 | 7 | 22 | <0.01 |
Positive stool test for adenovirus antigen | 10 | 32 | 15 | <0.01 |
Positive both tests for adenovirus antigen | 0 | 1 | 1 | <0.01 |
Group A (n = 57) | Group B (n = 40) | Group C (n = 38) | p * | |
---|---|---|---|---|
WBC (×103/μL Median; IQR) | 13.5 (10.3–18.9) | 12.3 (8.1–15.2) | 13.7 (9.2–18.7) | 0.29 |
ANC (×103/μL Median; IQR) | 6.8 (5–10.9) | 6.8 (4.7–10.7) | 6.4 (4.4–12.7) | 0.98 |
ALC (×103/μL Median; IQR) | 4.5 (2.9–6.6) | 2.8 (1.6–4.1) | 4.3 (2.9–5.9) | 0.001 |
PLT (×103/μL Median; IQR) | 308 (251–370) | 332 (273–405) | 325 (289–363) | 0.36 |
CRP (mg/L; Median; IQR) | 29.2 (10.4–69.1) | <5 (<5–20.6) | 28.7 (10.8–49.1) | <0.001 |
CRP among age groups (mg/L; Median; IQR) | ||||
<12 months | 21.5 (5.4–28) | 10.1 (<5–38.9) | 29.2 (18.2–57) | 0.566 |
12–24 months | 37.4 (12.7–69) | <5 (<5–19.3) | 23.5(7.2–46) | 0.025 |
>24 months | 30 (7–133) | <5 (<5–21.1) | 31.3 (10.8–56.4) | 0.013 |
Group A (n = 57) | Group B (n = 40) | Group C (n = 38) | p * | |
---|---|---|---|---|
Children with fever children (mg/L; median; IQR) | 30.2 (10.4–69.2) | 19.9 (13.3–6.3) | 40.6 (22–57) | 0.721 |
Children without fever (mg/L, median; IQR) | 15.7 (5.2–21.1) | <5 (<5–<5) | <5 (<5–10) | 0.019 |
Children who received antibiotics prior to admission (mg/L; median; IQR) | 29 (11.6–59) | 34 (<5–64) | 35.3 (14–49) | 0.97 |
Children without antibiotics prior to admission (mg/L; median;IQR) | 29.2 (6.9–121) | <5 (<5–19.3) | 26.4 (9.8–56) | 0.001 |
Children with LRTI (mg/L; median; IQR) | 24.3 (9–46) | N/D | 28.2 (9.5–49.1) | 1.0 |
Children without LRTI (mg/L;median;IQR) | 30.2 (10.4–115.6) | <5 (<5–20.6) | 35.8 (22.7–57.5) | 0.001 |
Children with AOM (mg/L; median; IQR) | 69.1 (12.8–154) | N/D | 24.9 (5–44.8) | 0.32 |
Children without AOM (mg/L;median;IQR) | 27.7 (9–60) | <5 (<5–20.6) | 28.7 (12–52.6) | 0.001 |
Group A (n = 57) | Group B (n = 40) | Group C (n = 38) | p * | |
---|---|---|---|---|
CRP > 15 mg/L | 39 (68%) | 14 (35%) | 26 (68%) | 0.002 |
CRP > 100 Mg/L | 12 (21%) | 1 (2.5%) | 3 (7.8%) | 0.016 |
CRP > 15 Mg/L | ||||
<12 months | 10 (66%) | 2 (50%) | 7 (77%) | 0.6 |
12–24 months | 16 (70%) | 5 (36%) | 12 (63%) | 0.11 |
>24 months | 13 (65%) | 7 (32%) | 7 (70%) | 0.044 |
CRP > 15 Mg/L | ||||
Fever | 37 (67%) | 12 (75%) | 24 (80%) | 0.44 |
No fever | 2 (67%) | 2 (8%) | 1 (14%) | 0.08 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ptak, K.; Szymońska, I.; Olchawa-Czech, A.; Baliga, Z.; Sawina, M.; Woźnica, A.; Kwinta, P. Different Clinical Manifestations of Adenoviral Infection Confirmed Using Point-of-Care Testing in a Group of Hospitalized Children. Pediatr. Rep. 2023, 15, 1-8. https://doi.org/10.3390/pediatric15010001
Ptak K, Szymońska I, Olchawa-Czech A, Baliga Z, Sawina M, Woźnica A, Kwinta P. Different Clinical Manifestations of Adenoviral Infection Confirmed Using Point-of-Care Testing in a Group of Hospitalized Children. Pediatric Reports. 2023; 15(1):1-8. https://doi.org/10.3390/pediatric15010001
Chicago/Turabian StylePtak, Katarzyna, Izabela Szymońska, Anna Olchawa-Czech, Zuzanna Baliga, Marta Sawina, Agata Woźnica, and Przemko Kwinta. 2023. "Different Clinical Manifestations of Adenoviral Infection Confirmed Using Point-of-Care Testing in a Group of Hospitalized Children" Pediatric Reports 15, no. 1: 1-8. https://doi.org/10.3390/pediatric15010001